PT2501703E - Compostos espiropiperidina como antagonistas do recetor orl-1 - Google Patents

Compostos espiropiperidina como antagonistas do recetor orl-1 Download PDF

Info

Publication number
PT2501703E
PT2501703E PT107824823T PT10782482T PT2501703E PT 2501703 E PT2501703 E PT 2501703E PT 107824823 T PT107824823 T PT 107824823T PT 10782482 T PT10782482 T PT 10782482T PT 2501703 E PT2501703 E PT 2501703E
Authority
PT
Portugal
Prior art keywords
methyl
mmol
pyran
piperidine
compound
Prior art date
Application number
PT107824823T
Other languages
English (en)
Portuguese (pt)
Inventor
Ana Belenbenito Collado
Nuria Diaz Buezo
Alma Maria Jimenez-Aguado
Celia Lafuente Blanco
Maria Angeles Martinez-Grau
Concepcion Pedregal-Tercero
Miguel Angel Toledo Escribano
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT2501703E publication Critical patent/PT2501703E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT107824823T 2009-11-16 2010-11-10 Compostos espiropiperidina como antagonistas do recetor orl-1 PT2501703E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382246 2009-11-16
US29862910P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
PT2501703E true PT2501703E (pt) 2013-11-26

Family

ID=41728051

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107824823T PT2501703E (pt) 2009-11-16 2010-11-10 Compostos espiropiperidina como antagonistas do recetor orl-1

Country Status (34)

Country Link
US (1) US8232289B2 (OSRAM)
EP (1) EP2501703B1 (OSRAM)
JP (1) JP5680101B2 (OSRAM)
KR (1) KR101363830B1 (OSRAM)
CN (1) CN102612520B (OSRAM)
AR (1) AR078863A1 (OSRAM)
AU (1) AU2010319581C1 (OSRAM)
CA (1) CA2796161C (OSRAM)
CO (1) CO6541545A2 (OSRAM)
CR (1) CR20130087A (OSRAM)
DK (1) DK2501703T3 (OSRAM)
DO (1) DOP2012000135A (OSRAM)
EA (1) EA020848B1 (OSRAM)
EC (1) ECSP12011902A (OSRAM)
ES (1) ES2435814T3 (OSRAM)
HN (1) HN2012001011A (OSRAM)
HR (1) HRP20130967T1 (OSRAM)
IL (1) IL219370A (OSRAM)
JO (1) JO2887B1 (OSRAM)
MA (1) MA33751B1 (OSRAM)
ME (1) ME01537B (OSRAM)
MX (1) MX2012005691A (OSRAM)
MY (1) MY160665A (OSRAM)
NZ (1) NZ600006A (OSRAM)
PE (1) PE20121430A1 (OSRAM)
PH (1) PH12012500969A1 (OSRAM)
PL (1) PL2501703T3 (OSRAM)
PT (1) PT2501703E (OSRAM)
RS (1) RS53018B (OSRAM)
SI (1) SI2501703T1 (OSRAM)
TW (1) TWI465453B (OSRAM)
UA (1) UA107943C2 (OSRAM)
WO (1) WO2011060035A1 (OSRAM)
ZA (1) ZA201202967B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388468B (es) 2009-12-04 2025-03-20 Sunovion Pharmaceuticals Inc Compuestos multicíclicos y métodos de uso de los mismos.
EP2630136A1 (en) * 2010-10-21 2013-08-28 Universität des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之orl-1受體拮抗劑
JP6313312B2 (ja) 2012-10-02 2018-04-18 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 農薬としての複素環化合物
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環(4.5)癸烷衍生物
AR105821A1 (es) * 2015-09-09 2017-11-15 Lilly Co Eli COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
WO2018023070A1 (en) 2016-07-29 2018-02-01 Sunovion Pharmaceuticals, Inc. Compounds and compositions and uses thereof
MY199446A (en) 2016-07-29 2023-10-28 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
AU2018220509B2 (en) 2017-02-16 2022-04-28 Sumitomo Pharma America, Inc. Methods of treating schizophrenia
SI3589638T1 (sl) 2017-03-02 2021-08-31 Eli Lilly And Company Spojine uporabne pri inhibiciji ROR-GAMMA-T
WO2018160547A1 (en) * 2017-03-02 2018-09-07 Eli Lilly And Company Compounds useful for inhibiting ror-gamma-t
KR20200036008A (ko) 2017-08-02 2020-04-06 선오비온 파마슈티컬스 인코포레이티드 이소크로만 화합물 및 이의 용도
MY208150A (en) 2018-02-16 2025-04-18 Sunovion Pharmaceuticals Inc Salts, crystal forms, and production methods thereof
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
JP7781768B2 (ja) 2020-04-14 2025-12-08 スミトモ・ファーマ・アメリカ・インコーポレイテッド 神経学的および精神障害の治療方法
MX2023002269A (es) 2020-08-26 2023-05-16 Vertex Pharma Inhibidores de apol1 y metodos para usar los mismos.
CA3251050A1 (en) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
EP1537110B1 (en) * 1999-12-06 2007-01-17 Euro-Celtique, S.A. Triazospiro compounds having nociceptin receptor affinity
YU82403A (sh) * 2001-04-18 2006-08-17 Euroceltique S.A. Jedinjenja spiropirazola
WO2002088089A1 (en) 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions
US7192964B2 (en) * 2001-07-23 2007-03-20 Banyu Pharmaceutical Co., Ltd. 4-oxoimidazolidine-2-spiropiperidine derivatives
WO2003064425A1 (en) * 2002-01-28 2003-08-07 Pfizer Japan Inc. N-substituted spiropiperidine compounds as ligands for orl-1 receptor
WO2003095427A1 (en) 2002-05-10 2003-11-20 Taisho Pharmaceutical Co.,Ltd. Spiro-ring compound
US6995168B2 (en) * 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
MXPA05002622A (es) * 2002-09-09 2005-09-08 Johnson & Johnson Derivados de 1,3,8,-triazaespiro [4.5]decan-4-ona sustituidos con hidroxialquilo utiles para el tratamiento de desordenes mediados por el receptor opioide huerfano.
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
BRPI0509377A (pt) * 2004-03-29 2007-09-11 Pfizer compostos de ácido alfa arila ou heteroaril metil beta piperidino propanóico como antagonistas do receptor orl1
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
JP5597188B2 (ja) * 2008-03-27 2014-10-01 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換されたスピロ環状シクロヘキサン誘導体

Also Published As

Publication number Publication date
JP2013510859A (ja) 2013-03-28
EA020848B1 (ru) 2015-02-27
EP2501703B1 (en) 2013-09-18
IL219370A (en) 2015-01-29
MX2012005691A (es) 2012-06-13
MY160665A (en) 2017-03-15
CA2796161A1 (en) 2011-05-19
PL2501703T3 (pl) 2014-02-28
AR078863A1 (es) 2011-12-07
DK2501703T3 (da) 2013-10-14
HK1169988A1 (en) 2013-02-15
WO2011060035A1 (en) 2011-05-19
SI2501703T1 (sl) 2013-11-29
DOP2012000135A (es) 2012-08-15
CN102612520A (zh) 2012-07-25
JP5680101B2 (ja) 2015-03-04
CN102612520B (zh) 2015-04-08
ME01537B (me) 2014-04-20
EA201290352A1 (ru) 2012-10-30
UA107943C2 (xx) 2015-03-10
AU2010319581C1 (en) 2014-05-15
JO2887B1 (en) 2015-03-15
CO6541545A2 (es) 2012-10-16
AU2010319581A1 (en) 2012-06-07
NZ600006A (en) 2014-05-30
EP2501703A1 (en) 2012-09-26
RS53018B (sr) 2014-04-30
ECSP12011902A (es) 2012-07-31
HRP20130967T1 (hr) 2013-11-22
HN2012001011A (es) 2015-08-31
PH12012500969A1 (en) 2013-01-07
KR20130026523A (ko) 2013-03-13
TWI465453B (zh) 2014-12-21
ZA201202967B (en) 2013-09-25
PE20121430A1 (es) 2012-10-26
ES2435814T3 (es) 2013-12-23
MA33751B1 (fr) 2012-11-01
KR101363830B1 (ko) 2014-02-14
US20110118251A1 (en) 2011-05-19
TW201127841A (en) 2011-08-16
US8232289B2 (en) 2012-07-31
CR20130087A (es) 2013-04-17
AU2010319581B2 (en) 2013-12-19
IL219370A0 (en) 2012-06-28
CA2796161C (en) 2015-03-17

Similar Documents

Publication Publication Date Title
PT2501703E (pt) Compostos espiropiperidina como antagonistas do recetor orl-1
ES2436241T3 (es) Compuestos de espiropiperidina como antagonistas de receptor oral-1
CN106061969B (zh) Trpa1调节剂
CN103298816A (zh) 作为激酶抑制剂的取代的吡唑并-喹唑啉衍生物
CN109526220A (zh) 用于治疗疼痛和疼痛相关的状况的四氢嘧啶并二氮杂*和四氢吡啶并二氮杂*化合物
JP2010520917A (ja) 肥満治療用三環式イソキノリン誘導体
ES2905582T3 (es) Derivados alcoxiamínicos para el tratamiento del dolor y las afecciones relacionadas con el dolor
HK1169988B (en) Spiropiperidine compounds as orl-1 receptor antagonists
BR112012012150A2 (pt) compostos spiro piperidina como antagonistas de recep-tor orl-1